WO1998040375A3 - COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS - Google Patents

COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS Download PDF

Info

Publication number
WO1998040375A3
WO1998040375A3 PCT/US1998/003792 US9803792W WO9840375A3 WO 1998040375 A3 WO1998040375 A3 WO 1998040375A3 US 9803792 W US9803792 W US 9803792W WO 9840375 A3 WO9840375 A3 WO 9840375A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
benzothiepines
bile acid
reductase inhibitors
acid transport
Prior art date
Application number
PCT/US1998/003792
Other languages
French (fr)
Other versions
WO1998040375A2 (en
Inventor
David B Reitz
Len F Lee
Jinglin J Li
Horng-Chih Huang
Samuel J Tremont
Raymond E Miller
Shyamal C Baneriee
Robert E Manning
Kevin C Glenn
Bradley T Keller
Original Assignee
Searle & Co
David B Reitz
Len F Lee
Jinglin J Li
Huang Horng Chih
Samuel J Tremont
Raymond E Miller
Shyamal C Baneriee
Robert E Manning
Kevin C Glenn
Bradley T Keller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1998040375(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA002283575A priority Critical patent/CA2283575A1/en
Priority to JP53959498A priority patent/JP2002500628A/en
Priority to NZ337830A priority patent/NZ337830A/en
Priority to IL13187298A priority patent/IL131872A0/en
Priority to BR9808013-0A priority patent/BR9808013A/en
Priority to HU0002395A priority patent/HUP0002395A3/en
Priority to EP98910075A priority patent/EP0971744A2/en
Application filed by Searle & Co, David B Reitz, Len F Lee, Jinglin J Li, Huang Horng Chih, Samuel J Tremont, Raymond E Miller, Shyamal C Baneriee, Robert E Manning, Kevin C Glenn, Bradley T Keller filed Critical Searle & Co
Priority to MXPA99008417A priority patent/MXPA99008417A/en
Priority to PL98336415A priority patent/PL336415A1/en
Priority to AU64408/98A priority patent/AU730024C/en
Priority to SK1250-99A priority patent/SK125099A3/en
Publication of WO1998040375A2 publication Critical patent/WO1998040375A2/en
Publication of WO1998040375A3 publication Critical patent/WO1998040375A3/en
Priority to NO994390A priority patent/NO994390L/en
Priority to BG103793A priority patent/BG103793A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Provided are novel benzothiepines, derivatives, and analogs thereof; pharmaceutical compositions containing them; and methods of using these compounds and compositions in medicine, particularly in the prophylaxis and treatment of hyperlipidemic conditions such as those associated with atherosclerosis or hypercholesterolemia, in mammals. Also provided are compositions and methods for combination therapy employing ileal bile acid transport inhibitors and HMG Co-A reductase inhibitors for the treatment of hyperlipidemic conditions.
PCT/US1998/003792 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS WO1998040375A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SK1250-99A SK125099A3 (en) 1997-03-11 1998-03-10 Combination of ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
EP98910075A EP0971744A2 (en) 1997-03-11 1998-03-10 COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
NZ337830A NZ337830A (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
IL13187298A IL131872A0 (en) 1997-03-11 1998-03-10 Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
MXPA99008417A MXPA99008417A (en) 1997-03-11 1998-03-10 COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS.
HU0002395A HUP0002395A3 (en) 1997-03-11 1998-03-10 Combined pharmaceutical compositions containing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
JP53959498A JP2002500628A (en) 1997-03-11 1998-03-10 Combination therapy using benzothiepine and HMG Co-A reductase inhibitor inhibiting ileal bile acid transport
CA002283575A CA2283575A1 (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
BR9808013-0A BR9808013A (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and co-a hmg reductase inhibitors
PL98336415A PL336415A1 (en) 1997-03-11 1998-03-10 Combined therapy employing ileic bile acid transport inhibiting benzothiepins as well as a hmg co-enzyme reductase inhibitors
AU64408/98A AU730024C (en) 1997-03-11 1998-03-10 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
NO994390A NO994390L (en) 1997-03-11 1999-09-10 Combination therapy using ileal bile acid transport inhibitory benzothepines and HMG Co-A reductase inhibitors
BG103793A BG103793A (en) 1997-03-11 1999-10-11 COMBINED THERAPY USING BENZOTHIAPINS INHIBITING THE ILEAL BILE ACID TRANSPORT AND HMG Co-A REDUCTASE INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
US60/040,660 1997-03-11

Publications (2)

Publication Number Publication Date
WO1998040375A2 WO1998040375A2 (en) 1998-09-17
WO1998040375A3 true WO1998040375A3 (en) 1998-12-03

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Country Status (16)

Country Link
EP (1) EP0971744A2 (en)
JP (1) JP2002500628A (en)
CN (1) CN1255864A (en)
AU (1) AU730024C (en)
BG (1) BG103793A (en)
BR (1) BR9808013A (en)
CA (1) CA2283575A1 (en)
HU (1) HUP0002395A3 (en)
IL (1) IL131872A0 (en)
MX (1) MXPA99008417A (en)
NO (1) NO994390L (en)
NZ (1) NZ337830A (en)
PL (1) PL336415A1 (en)
RU (1) RU2247579C2 (en)
SK (1) SK125099A3 (en)
WO (1) WO1998040375A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (en) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
US20020061888A1 (en) * 2000-03-10 2002-05-23 Keller Bradley T. Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (en) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
RU2305681C2 (en) 2001-09-08 2007-09-10 Астразенека Аб Benzothiadiazepine derivatives and method for production thereof (variants)
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
TW200303302A (en) 2001-12-19 2003-09-01 Atherogenics Inc Chalcone derivatives and their use to treat diseases
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CA2497345C (en) * 2002-08-28 2008-10-14 Asahi Kasei Pharma Corporation Novel quaternary ammonium compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (en) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 Novel benzothiazepine and benzothiepine compounds
WO2011150286A2 (en) 2010-05-26 2011-12-01 Satiogen Pharmaceuticals,Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
AU2011326872C1 (en) 2010-11-08 2015-02-19 Albireo Ab A pharmaceutical combination comprising an IBAT inhibitor and a bile acid binder
BR112013010157B1 (en) 2010-11-08 2020-02-04 Albireo Ab ibat inhibitors, their uses, and pharmaceutical composition and combinations
KR102051030B1 (en) 2011-10-28 2019-12-02 루메나 파마수티컬즈, 인코포레이티드 Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CN104023718B (en) 2011-10-28 2017-04-05 鲁美纳医药公司 For treating the bile acid recycling inhibitors of high cholemia and cholestatic liver disease
CA2907214A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of barrett's esophagus and gastroesophageal reflux disease
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
JP6661643B2 (en) 2014-09-28 2020-03-11 フアフイ ヘルス リミテッドＨｕａｈｕｉ Ｈｅａｌｔｈ Ｌｔｄ． Inhibition of hepatitis B and D virus and NTCP transport by polymerized bile acid derivatives
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
JP6954927B2 (en) 2016-02-09 2021-10-27 アルビレオ・アクチボラグ Oral cholestyramine preparation and its use
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874669T3 (en) 2016-02-09 2021-11-05 Albireo Ab Oral formulation of cholestyramine and its use
JP2020530448A (en) 2017-08-09 2020-10-22 アルビレオ・アクチボラグ Cholestyramine granules, oral cholestyramine preparations, and their use
CA3071182A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine pellets, oral cholestyramine formulations and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
ES2942443T3 (en) 2018-06-05 2023-06-01 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
CN112262130A (en) 2018-06-20 2021-01-22 阿尔比里奥公司 Crystal modification of odexibart
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
MX2021008981A (en) 2019-02-06 2021-09-08 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators.
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN113453753A (en) 2019-02-06 2021-09-28 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
CA3129827A1 (en) 2019-02-12 2020-08-20 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
TW202134220A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134222A (en) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 Benzothia(di)azepine compounds and their use as bile acid modulators
CN114786772B (en) 2019-12-04 2024-04-09 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
JP2023504644A (en) 2019-12-04 2023-02-06 アルビレオ・アクチボラグ Benzothiadiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
PL4069360T3 (en) 2019-12-04 2024-04-29 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
AR120682A1 (en) 2019-12-04 2022-03-09 Albireo Ab BENZOTHIADIAZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
PT4069360T (en) 2019-12-04 2024-03-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
EP4188541A1 (en) 2020-08-03 2023-06-07 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (en) * 2020-11-23 2022-10-14 郑州大学 Preparation method of cholesterol oxidase modified hybrid metal organic framework tumor targeting nano preparation
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis
US20240140922A1 (en) * 2022-08-22 2024-05-02 Enanta Pharmaceuticals, Inc. Fused heterobicyclic antiviral agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOCHIMICA ET BIOPHYSICA ACTA, 1227 (3). 1994. 137-154. *
BIOLOGICAL ABSTRACTS, vol. 11, Philadelphia, PA, US; abstract no. 317019, WESS G ET AL: "Synthesis and biological activity of bile acid-derived HMG-CoA reductase inhibitors: The role of 21-methyl in recognition of HMG-CoA reductase and the ileal bile acid transport system" XP002078626 *
BIOLOGICAL ABSTRACTS, vol. 11, Philadelphia, PA, US; abstract no. 489744, KRAMER W ET AL: "Bile acid derived HMG-CoA reductase inhibitors" XP002078625 *
JOURNAL OF MEDICINAL CHEMISTRY, 37 (20). 1994. 3240-3246. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof

Also Published As

Publication number Publication date
BR9808013A (en) 2001-09-25
NO994390L (en) 1999-11-04
AU730024C (en) 2004-08-05
SK125099A3 (en) 2001-02-12
EP0971744A2 (en) 2000-01-19
AU6440898A (en) 1998-09-29
CN1255864A (en) 2000-06-07
CA2283575A1 (en) 1998-09-17
RU2247579C2 (en) 2005-03-10
HUP0002395A3 (en) 2002-12-28
JP2002500628A (en) 2002-01-08
HUP0002395A2 (en) 2001-05-28
BG103793A (en) 2000-07-31
MXPA99008417A (en) 2005-02-03
AU730024B2 (en) 2001-02-22
WO1998040375A2 (en) 1998-09-17
NZ337830A (en) 2001-07-27
NO994390D0 (en) 1999-09-10
IL131872A0 (en) 2001-03-19
PL336415A1 (en) 2000-06-19

Similar Documents

Publication Publication Date Title
WO1998040375A3 (en) COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS
AP2001002062A0 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake.
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
GR3035583T3 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
BG103190A (en) Substituted pyrimidine derivatives and their pharmaceutical application
WO2000047568A3 (en) 1,2-benzothiazepines for the treatment of hyperlipidemic diseases
AU6958996A (en) Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU1973997A (en) Pentafluorobenzenesulfonamides and analogs
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
CA2356422A1 (en) Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
EP0433842A3 (en) 1,2,3-triazole derivatives active as inhibitors of the enzyme hmg-coa reductase and pharmaceutical compositions containing them
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
ZA933768B (en) Novel phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism metabolism.
AU8033594A (en) Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof
TW268937B (en)
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
AU3481795A (en) Pharmaceutical compositions containing d2o
WO1996022305A3 (en) Modified peptides
AU5816496A (en) Process for the depyrogenation of injectable pharmaceutical solutions
AU2670600A (en) Pharmaceutical composition containing desoxypeganine for the treatment of nicotine dependence
AU7812794A (en) Pharmaceutical compositions containing n-acetylcarnosine for the treatment of cataract
AU6187394A (en) New pyrrolopyrazine compounds, processes for their preparation and the pharmaceutical compositions which contain them
IL111144A0 (en) Pharmaceutical compositions containing amiodarone for the treatment of heart failure
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 131872

Country of ref document: IL

Ref document number: 98804995.3

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2283575

Country of ref document: CA

Ref document number: 2283575

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 125099

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 1019997008341

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 1998 539594

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/1999/008417

Country of ref document: MX

Ref document number: 64408/98

Country of ref document: AU

Ref document number: PV1999-3228

Country of ref document: CZ

Ref document number: 99-00975

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 337830

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1998910075

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1998910075

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1999-3228

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1019997008341

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 64408/98

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: PV1999-3228

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: 1019997008341

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1998910075

Country of ref document: EP